In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential pharmacotherapies for the treatment of obesity and non-insulin dependent (type II) diabetes, we prepared a novel series of phenylethanolamine derivatives containing acetanilides and evaluated their biological activities at the human β3-, β2-, and β1-ARs. Among these compounds, the 6-amino-2-pyridylacetanilide (36b), 2-amino-5-methylthiazol-4-ylacetanilide (36g), and 5-amino-1,2,4-thiadiazol-3-ylacetanilide (36h) derivatives showed potent agonistic activity at the β3-AR with functional selectivity over the β1- and β2-ARs. In addition, these compounds exhibited significant hypoglycemic activity in a rodent diabetic model.
在寻找有效且选择性的人类β3-
肾上腺素受体(AR)激动剂作为治疗肥胖和非
胰岛素依赖型(2型)糖尿病的潜在药物治疗时,我们准备了一系列新颖的含有
醋酸酰胺的
苯乙醇胺衍
生物,并评估了它们在人体β3-、β2-和β1-AR上的
生物活性。在这些化合物中,6-
氨基-2-
吡啶基
醋酸酰胺(36b)、
2-氨基-5-甲基噻唑-4-基
醋酸酰胺(36g)和
5-氨基-1,2,4-噻二唑-3-基
醋酸酰胺(36h)衍
生物在β3-AR上显示出强烈的激动活性,并且对β1-和β2-AR具有功能选择性。此外,这些化合物在啮齿动物糖尿病模型中还表现出显著的降血糖活性。